10 results about "Cefixime" patented technology

The application discloses application of antibacterial peptide BMAP-28 and antibiotics in combined preparation of antibacterial drugs and belongs to the technical field of biological medicine. The antibiotics are selected from one or more of the following: ciprofloxacin, gentamicin and cefixime. The application combines the antibacterial peptide BMAP-28 with antibiotics such as ciprofloxacin and gentamicin, finds that the combination has a significant synergistic antibacterial effect on Enterobacter sakazii, can greatly save the dosage of the drug, reduce the toxic side effect and block the evolution process of drug resistance. Through the destruction of the bacterial cell membrane and the assistance of the antibiotic effect, the combination can effectively overcome the multiple drug resistance, widen the antibacterial spectrum and has a wide clinical application prospect.

Neisseria gonorrhoeae is one of the most common bacterial sexually transmitted infections (STI). Diagnosis depends on standard nucleic acid amplification testing (NAAT), which is impracticable in most low-resource settings, where the prevalence of this STI is highest. Consequently, such areas utilize syndromic management, which misses a high proportion of cases and leads to antibiotic overuse, contributing to the troubling rise of resistance to the commonly prescribed ciprofloxacin, cefixime and ceftriaxone antibiotics for the treatment of N. gonorrhoeae infections. A specific, highly sensitive and cost-effective lateral flow assay is disclosed that utilizes CRISPR-Cas orthologs, multiplex SHERLOCK technology and isothermal amplification via recombinase polymerase amplification (RPA) for the rapid detection of antibiotic resistance to ciprofloxacin, cefixime and / or ceftriaxone at the point of care. This approach has the potential to increase treatment efficacy in the field and mitigate the spread of antibiotic resistance.

The invention discloses a preparation method and application of an aromatic dicarboxylic acid-terbium complex fluorescent sensor array. The fluorescent sensor array comprises three fluorescent probes, the terbium complexes are respectively a 5-methoxy isophthalic acid-terbium complex, a 5-hexadecyloxy isophthalic acid-terbium complex and a 5-(6 '-cholesterol) hexyloxy isophthalic acid-terbium complex, and the preparation method comprises the following steps: (1) dissolving an aromatic dicarboxylic acid ligand in DMSO (dimethylsulfoxide) to obtain an aromatic dicarboxylic acid ligand mother solution; dissolving a terbium source in distilled water to obtain terbium ion mother liquor; and (2) adding the terbium ion mother liquor into an HEPES buffer solution, adding an aromatic dicarboxylic acid ligand mother liquor into the HEPES buffer solution, and carrying out constant-temperature reaction at 30-40 DEG C for 40-95 minutes to obtain the aromatic dicarboxylic acid-terbium complex. The fluorescent sensor array can be used for detecting tetracycline, cefixime, chloramphenicol and ciprofloxacin, and is high in accuracy and sensitive.

The application belongs to the technical field of pharmacy and relates to a method for preparing cefixime by using an enzyme method. The method comprises the following steps: performing an enzymatic hydrolysis reaction on cefixime alkyl ester in water in the presence of a hydrolytic enzyme at a pH of 7-8.5 to obtain cefixime. According to the method for preparing cefixime by using the enzyme method, the reaction condition becomes milder, the generation of impurities in the reaction process is effectively controlled, and the product quality and yield of cefixime are both improved.

This invention relates to the field of pharmaceutical chemical synthesis technology, specifically disclosing a method for preparing a stable cefixime side-chain acid active ester. The invention involves adding dibenzothiazole disulfide, cefixime side-chain acid, an organic amine, and triethyl phosphite to a reaction solvent for a condensation reaction; then adding a crystallization solvent to the reaction system, cooling to allow crystallization, separating the solid and liquid phases, and washing the resulting solid with a phosphate buffer to obtain the cefixime side-chain acid active ester; the particle size of the dibenzothiazole disulfide is D90 = 20 μm~45 μm; the pH of the phosphate buffer is neutral. This invention couples the condensation reaction and crystallization process into one step, synergistically adding an organic amine and triethyl phosphite, purifying with a specific neutral phosphate buffer, and controlling the particle size of the raw material DM, achieving product quality assurance throughout the entire process from reaction source to purification. Accelerated testing has confirmed that the sample exhibits high stability.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to cefixime granules and a preparation method thereof. The cefixime granules provided by the invention are prepared from cefixime, a dissolution-promoting and stability-maintaining agent and pharmaceutically acceptable auxiliary materials, wherein the dissolution-promoting and stability-maintaining agent is a combination of sodium caprylate and meglumine; meanwhile, the dissolution-promoting stability-maintaining agent and the cefixime are subjected to a specific pretreatment process, and then the cefixime particles are prepared through a wet granulation process. According to the technical scheme, the dissolution performance and the stability of the cefixime granules are synergistically optimized, and the preparation process is simple, convenient and controllable, does not need to depend on a special high-energy-consumption process, has relatively high industrial feasibility and is beneficial to large-scale production and market promotion.

This application relates to the field of continuous crystallization technology and provides a method for continuous crystallization of cefixime. The method includes: preheating a cefixime-containing solution to be crystallized, adding an aqueous hydrochloric acid solution for mixing to obtain a primary mixture; adjusting the pH of the primary mixture and stirring for a first crystallization; continuing to add an aqueous hydrochloric acid solution for mixing to obtain a secondary mixture; adjusting the pH of the secondary mixture, cooling, stirring, and performing a second crystallization to obtain a crystalline liquid; centrifuging the crystalline liquid to obtain a mother liquor; cooling the mother liquor, stirring, and performing a third crystallization to obtain the finished product; or cooling the crystalline liquid, stirring, performing a third crystallization, centrifuging, and then obtaining the finished product. The continuous crystallization method for cefixime described in this application can improve production yield and continuously produce cefixime raw materials with a required particle size distribution.

The invention relates to the technical field of chromatographic detection, in particular to a method for determining the concentration of cefixime in K2EDTA human plasma through liquid chromatography-tandem mass spectrometry. Comprising the following steps: preparing a standard curve solution containing cefixime-13C-15N2 by using K2EDTA (Ethylene Diamine Tetraacetic Acid) human plasma as a matrix, preparing a test solution containing cefixime, and precipitating the solutions by using acetonitrile; determining the concentration of the cefixime test solution after precipitation by using an internal standard method; a liquid chromatography tandem mass spectrometer is used for determination, a mobile phase of liquid chromatography is composed of a mobile phase A and a mobile phase B, the mobile phase A is an aqueous solution containing 10 mM ammonium acetate, and the mobile phase B is acetonitrile. The invention provides an efficient and accurate cefixime concentration detection method by optimizing chromatographic conditions and mass spectrum parameters, so that the accuracy and reliability of data are ensured, and the requirements of biological sample analysis in clinical tests are met.

The invention relates to a preparation method of a cefixime intermediate, which belongs to the technical field of drug intermediate synthesis, and comprises the following steps: 1, synthesizing an oxime ether intermediate by using tert-butyl acetoacetate as an initial raw material and using a two-step one-pot method; in the second step, a chlorination-cyclization one-pot reaction is adopted, wherein the oxime ether intermediate reacts with NOCl generated by hydrochloric acid and tert-butyl nitrite, and a chlorination product is generated; carrying out cyclization reaction with thiourea and triethylamine to obtain an acid intermediate; and 3, in order to avoid decomposition of the product, respectively pulping the acid intermediates-dichloromethane, DM-triethylamine and triphenylphosphine-dichloromethane, and mixing and reacting in the microchannel to finally obtain the cefixime intermediate. The whole synthesis route avoids strong acid and other raw materials with great environmental pollution, avoids generation of byproducts, obtains high-yield and high-purity products, and shows better economic advantages.

The application discloses a kind of adhering arrow bacteria DLW198 and application.It belongs to the technical field of antibiotic degradation.The adhering arrow bacteria DLW198 of the application can tolerate the concentration of cefoperazone is 50-250mg / L, the inoculation amount of adhering arrow bacteria is 5%-25%, the degradation temperature is 20-40 DEG C, and pH is 5-9, under the above conditions, adhering arrow bacteria can effectively degrade cefoperazone.Under the conditions of temperature 30 DEG C, pH 7, inoculation amount 20%, and rotation speed 200r / min, the degradation rate of strain DLW198 to 200mg / L cefoperazone reaches 92.98% in 16h.In addition, strain DLW198 can also degrade cephalexin, ceftriaxone sodium, cefixime and amoxicillin.The strain has higher biological safety, and will not endanger human health or pollute the environment in the application process, and has important application value.